Research programme: small molecule therapeutics - Avalon/Novartis

Drug Profile

Research programme: small molecule therapeutics - Avalon/Novartis

Latest Information Update: 19 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avalon Pharmaceuticals; Novartis
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 19 Jul 2010 Discontinued for Undefined indication in USA (unspecified route)
  • 21 Aug 2009 Development is ongoing in USA
  • 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top